{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016259","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.319194+00:00","generated_at":"2026-06-24T01:33:41.422396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vera Therapeutics Q2 net loss $14.9M, cash $131.9M; Phase 2b atacicept enrollment complete","bullets":["Net loss of $14.9M ($0.55 per share) vs $3.4M ($0.33) in Q2 2021.","Cash, equivalents, and securities $131.9M at June 30, 2022; plus $45M credit facility.","Completed enrollment in Phase 2b ORIGIN trial of atacicept for IgA nephropathy; topline data expected early Q1 2023.","Appointed Michael M. Morrissey, Ph.D., CEO of Exelixis, as Chairman of the board.","Plan to initiate Phase 3 atacicept trial in lupus nephritis in H2 2022 and Phase 2b/3 MAU868 in BKV in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016259","json":"https://secwatch.observer/filing/0000950170-22-016259.json","markdown":"https://secwatch.observer/filing/0000950170-22-016259.md","text":"https://secwatch.observer/filing/0000950170-22-016259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017022016259/0000950170-22-016259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017022016259/vera-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:33:41.422396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}